Brokers Issue Forecasts for RYTM FY2026 Earnings

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Equities researchers at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for Rhythm Pharmaceuticals in a report issued on Monday, March 3rd. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($1.49) per share for the year. HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.03). The business had revenue of $41.83 million for the quarter, compared to analyst estimates of $38.48 million. Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%.

Several other research analysts have also recently weighed in on RYTM. Needham & Company LLC restated a “buy” rating and set a $64.00 target price on shares of Rhythm Pharmaceuticals in a report on Thursday, February 27th. The Goldman Sachs Group boosted their price objective on Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Oppenheimer assumed coverage on Rhythm Pharmaceuticals in a report on Friday, December 20th. They issued an “outperform” rating and a $76.00 target price for the company. Stifel Nicolaus initiated coverage on Rhythm Pharmaceuticals in a report on Wednesday. They set a “buy” rating and a $78.00 price target on the stock. Finally, Canaccord Genuity Group upped their price objective on shares of Rhythm Pharmaceuticals from $80.00 to $81.00 and gave the company a “buy” rating in a report on Thursday, February 27th. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $69.08.

Rhythm Pharmaceuticals Trading Down 0.5 %

RYTM opened at $52.97 on Wednesday. Rhythm Pharmaceuticals has a twelve month low of $35.17 and a twelve month high of $68.58. The firm has a market capitalization of $3.26 billion, a PE ratio of -12.23 and a beta of 2.30. The firm’s 50-day moving average price is $56.79 and its 200 day moving average price is $54.48.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Rhythm Pharmaceuticals in the fourth quarter valued at approximately $4,259,000. GF Fund Management CO. LTD. acquired a new stake in Rhythm Pharmaceuticals during the 4th quarter worth approximately $72,000. Voloridge Investment Management LLC boosted its position in Rhythm Pharmaceuticals by 7.7% in the 4th quarter. Voloridge Investment Management LLC now owns 380,537 shares of the company’s stock valued at $21,302,000 after buying an additional 27,214 shares during the period. Two Sigma Advisers LP grew its stake in shares of Rhythm Pharmaceuticals by 2.3% in the fourth quarter. Two Sigma Advisers LP now owns 13,100 shares of the company’s stock worth $733,000 after acquiring an additional 300 shares in the last quarter. Finally, State of Wyoming acquired a new position in shares of Rhythm Pharmaceuticals in the fourth quarter worth $61,000.

Insider Activity

In other news, EVP Jennifer Kayden Lee sold 1,447 shares of Rhythm Pharmaceuticals stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total value of $85,995.21. Following the completion of the sale, the executive vice president now directly owns 4,038 shares of the company’s stock, valued at approximately $239,978.34. The trade was a 26.38 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Joseph Shulman sold 1,281 shares of the business’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $59.43, for a total value of $76,129.83. Following the completion of the sale, the insider now owns 2,657 shares in the company, valued at $157,905.51. This represents a 32.53 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,787 shares of company stock valued at $1,901,443. Company insiders own 5.60% of the company’s stock.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.